Boehringer Ingelheim’s Anti-Sema3A BI 764524 Shows Promise in Diabetic Macular Ischemia Trial
Boehringer Ingelheim (BI) has announced the publication of results from a Phase I/IIa clinical trial...
Pfizer Pauses Dosing in DMD Gene Therapy Trial Following Participant’s Sudden Death
This week, Pfizer Inc. (NYSE: PFE) announced the unfortunate sudden death of a participant in...
Tonghua Dongbao Pharmaceuticals Inks Licensing Deal for Semaglutide in China
Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has entered into a licensing agreement...
J&J’s Erleada Plus ADT Shows 0% Biochemical Recurrence Rate in High-Risk Prostate Cancer Trial
Johnson & Johnson (J&J; NYSE: JNJ) has announced that its Phase II clinical trial for...
China’s Sciwind Biosciences Partners with HK inno.N for Ecnoglutide Rights in South Korea
China’s Sciwind Biosciences Co., Ltd has entered into a licensing and partnership agreement with South...
Siemens Healthineers Reports 3% YOY Growth in Q2 2024 Fiscal Report Amidst Challenging Comparison
Germany’s medical technology leader Siemens Healthineers AG (ETR: SHL) has reported its financial results for...
AstraZeneca Hong Kong Launches ‘HRDetect’ Program to Offer Free Genetic Testing for Cancer Patients
AstraZeneca (AZ, NASDAQ: AZN) Hong Kong has announced a partnership with Inocras Hong Kong Ltd...
Siemens Healthineers AG Forges Expanded Partnership with Xi’an Daixing Hospital
Germany’s Siemens Healthineers AG (ETR: SHL) has entered into an eight-year value partnership with Xi’an...
Everest Medicines’ Velsipity for UC Receives First Asian Approval in Macau
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that the regulatory authority in...
Wanbangde Pharmaceutical’s Huperzine A Earns FDA Rare Pediatric Disease Designation for HIE Treatment
China’s Wanbangde New Building Materials Co., Ltd (SHE: 002082) has announced that its subsidiary, Wanbangde...
Andon Health’s Triplex Virus Test Kit Receives US FDA Emergency Use Authorization
Andon Health Co., Ltd (SHE: 002432), a leading healthcare company based in China, has announced...
Citi Pharma Ltd and Hangzhou Newsea Technology Form JV to Boost API Production
Pakistan-based pharmaceutical company Citi Pharma Ltd is entering into a joint venture (JV) agreement with...
Medtronic’s RDN System Symplicity Spyral Earns First-Ever NMPA Approval
Medtronic (NYSE: MDT), the US-Irish medical device giant, has announced that its Symplicity Spyral renal...
Xi and Macron Discuss Enhanced Market Access for Foreign Investors, Focus on Life Sciences
This week, talks between China’s President Xi Jinping and France’s President Emmanuel Macron in France...
LEO Pharma’s Enstilar Outperforms Daivobet in Phase III Psoriasis Trial in China
Denmark-based dermatology specialist LEO Pharma A/S has announced positive outcomes for its drug candidate Enstilar...
Ono Pharmaceutical Secures Deal to Acquire Deciphera Pharmaceuticals for USD 2.4 Billion
Japan-based Ono Pharmaceutical Co., Ltd (TYO: 4528) has announced that it has reached an agreement...
Mabwell Bioscience’s 9MW2821 Earns Orphan Drug Status from FDA for Esophageal Cancer
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...
Innovent Biologics’ CLDN18.2 ADC IBI343 Receives Breakthrough Designation in China
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...
Yantai Dongcheng Pharmaceutical’s Radiopharmaceutical 18F-LNC1007 Cleared for Australian Phase I Trial
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has announced that...
Sichuan Biokin’s EGFR/HER3 ADC Expands Phase II Clinical Program with NMPA Approval
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a Chinese biopharmaceutical company, has received approval from...